Biotech Investing

Q BioMed 'looking for a significant return for shareholders' – CEO Denis Corin

Biotech Investing

Denis Corin, chief executive of Q BioMed Inc. (OTCQB:QBIO) ) tells Proactive’s Andrew Scott their objective is to find innovative, under-valued and under-appreciated biotech assets out in the pharma world and bring them in-house through licensing and option agreements. ”[We’re] agnostic in terms of exit …. as long as there’s a significant return for shareholders”, …

Denis Corin, chief executive of Q BioMed Inc. (OTCQB:QBIO) ) tells Proactive’s Andrew Scott their objective is to find innovative, under-valued and under-appreciated biotech assets out in the pharma world and bring them in-house through licensing and option agreements.
”[We’re] agnostic in terms of exit …. as long as there’s a significant return for shareholders”, Corin says.

Watch Full Interview here

Click here to connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.

Source: www.proactiveinvestors.com

Biotech Investing

MARKETS

Markets
TSX	20214.69	-4.20
TSXV	577.39	-4.33
DOW	34440.88	-76.85
S&P 500	4402.20	-41.75
NASD	13469.13	-209.06
ASX	7163.30	-33.30

COMMODITIES

Commodities
Gold	1929.53	+0.32
Silver	23.25	+0.11
Copper	3.74	-0.04
Palladium	1713.17	0.00
Platinum	1087.26	0.00
Oil	88.89	-0.77
Heating Oil	3.23	-0.01
Natural Gas	2.74	0.00

DOWNLOAD FREE REPORTS

BROWSE COMPANIES BY SECTOR